Responsive Image

 

 

Responsive Image

Enfermedades autoinmunes

Líneas de investigación

Análisis del riesgo vascular.
Arteriopatía subclínica en el LES y el SAF.
Determinantes genéticos de trombosis en pacientes con anticuerpos antifosfolípido.
Impacto de los corticoides en el pronóstico del lupus.

Foto grupo

Actividades del grupo

Nuestro grupo de investigación desarrolla su actividad en el seno de la Sección de Enfermedades Autoinmunes del Servicio de Medicina Interna del Hospital Universitario Cruces. Acumulamos una dilatada experiencia clínica con pacientes afectos de lupus eritematoso sistémico (LES), síndrome antifosfolípido (SAF), esclerosis sistémica, síndrome de Sjögren y otras enfermedades autoinmunes. Somos una Unidad referente a nivel de la Comunidad Autónoma Vasca y desarrollamos, además, una intensa labor docente en este campo, contribuyendo a la formación específica de residentes de diversos hospitales españoles. Pertenecemos desde su constitución inicial al Grupo de  Enfermedades Autoinmunes Sistémicas (GEAS) de la Sociedad Española de Medicina Interna (SEMI), con plena implicación tanto en la organización de programas formativos como en el desarrollo de proyectos de investigación multicéntricos, algunos de los cuales lideramos.

Como Unidad integrada en un Hospital Universitario de tercer nivel y con especial dedicación a la medicina de alta complejidad, entendemos que la investigación está íntimamente ligada a nuestra actividad clínica. De hecho, la enfocamos como una herramienta que permite responder preguntas relacionadas con la práctica diaria, con una traslación inmediata a la aplicación específica en nuestros pacientes.

En el capítulo investigador somos un grupo consolidado en el campo del LES y SAF. Nuestra investigación se centra fundamentalmente en aspectos clínicos y se basa en la recogida de datos observacionales. Dada la relativa rareza de estas enfermedades y su heterogeneidad, los estudios de cohortes prospectivas son una herramienta de investigación habitual en este campo, de hecho gran parte de la práctica clínica en estos pacientes está basada en estudios observacionales.

De nuestras contribuciones, queremos destacar los estudios que han identificado el SAF como un factor pronóstico adverso en pacientes con LES; los que han establecido los importantes efectos beneficiosos a largo plazo de los antipalúdicos en el lupus, incluyendo una mayor supervivencia; los que han definido el nivel de anticoagulación ideal en el SAF; o los que han contribuido a clarificar el papel de la vitamina D en el lupus.

En este momento tenemos en marcha líneas activas que se centran, entre otros aspectos, en el análisis del riesgo vascular y la arteriopatía subclínica en el LES y el SAF, en los determinantes genéticos de trombosis en pacientes con anticuerpos antifosfolípido o en el impacto de los corticoides en el pronóstico del lupus.

Mantenemos desde hace más de 10 años una colaboración estable con el grupo del Dr. Munther Khamashta, que dirige la Lupus Research Unit del St. Thomas' Hospital de Londres. Somos el único grupo español miembro de pleno derecho de SLICC (Systemic Lupus International Collaborating Clinics), grupo internacional de investigación en red que reúne a muchos de los principales investigadores internacionales en el campo del lupus. Formamos parte de los grupos de investigación de lupus, esclerodermia, vasculitis y terapias biológicas (BIOGEAS) del GEAS, y coordinamos el Registro Español de Lupus Eritematoso Sistémico (RELES), la primera cohorte de incepción a nivel nacional, que cuenta ya con más de 150 pacientes en seguimiento prospectivo. Igualmente, compartimos proyectos con el grupo liderado por la Profesora Ana Zubiaga, del Departamento de Genética, Antropología física y Fisiología animal de la UPV/EHU. Más recientemente, nos hemos sumado como colaboradores a los estudios genéticos multicéntricos en el campo de la esclerosis sistémica y las vasculitis que lidera el Dr. Javier Martín, del Instituto de Parasitología y Biomedicina López-Neyra de Granada.

Proyectos Activos:

Factores pronósticos en el lupus eritematoso sistémico. Cohorte observacional lupus-cruces
Prevalencia y factores de riesgo de enfermedad cardiovascular en el lupus eritematoso sistémico
Estudio de las manifestaciones neuropsiquiátricas en el lupus
Variables asociadas al riesgo de neoplasias en el lupus eritematoso sistémico
Estudio de la frecuencia y factores predictores de toxicidad retiniana en pacientes con lupus en tratamiento con antipalúdicos
Definición y validación de escalas de actividad en  lupus
Identificación de variables predictivas de trombosis en individuos con anticuerpos antifofolípido
Identificación de genes de susceptibilidad al síndrome antifosfolípido.
Prevalencia y factores de riesgo de enfermedad cardiovascular en el síndrome antifosfolípido
Factores pronósticos en el la esclerosis sistemica
Factores pronósticos en las miopatías inflamatorias
Factores pronósticos en las vasculitis sistémicas
Identificación de genes de susceptibilidad a la enfermedad de behçet
Eficacia y efectos adversos de los tratamientos biológicos en las enfermedades autoinmunes sistémicas
Estudio de los factores causales y pronósticos de preeclampsia
Estudio de las complicaciones y factores pronósticos en el embarazo de mujeres con enfermedades autoinmunes sistémicas

Coordinador/a del grupo



Miembros del grupo

  Mónica Ferreiro Montenegro
 
 
  Cristina González de Echevarri Pérez de Heredia
 
 
  Daniel Martín Iglesias
 
 
  Ioana Ruiz Arruza
 
 
  Beatriz Ruiz Estévez
 
 
  Amaia Ugarte Núñez
 
 
  Mikel Olmo Velasco
 
 
  Adriana Soto Peleteiro
 
 

Publicaciones del grupo

Almeida Brasil CC, Hanly JG, Urowitz M, Clarke AE, Ruiz Irastorza G, Gordon C, et al. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022; 81(3): 370-378. DOI:10.1136/annrheumdis-2021-221295.

Moreno Torres V, Royuela A, Tarin C, Castejon R, Gutierrez Rojas A, Duran Del Campo P, et al. Impact of cardiovascular risk factors in antiphospholipid syndrome: an observational study from the Spanish national registry. Clin Exp Rheumatol. 2022; 40(11): 2161-2166. DOI:10.55563/clinexprheumatol/h2tkx3.

Choi MY, Clarke AE, Urowitz M, Hanly J, St Pierre Y, Gordon C, et al. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2022; 81(8): 1143-1150. DOI:10.1136/annrheumdis-2022-222168.

Lledo GM, Xipell M, Garcia Herrera A, Bueno L, Cervera R, Galindo M, et al. Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. Eur J Intern Med. 2022; 99: 19-21. DOI:10.1016/j.ejim.2022.03.016.

Guillen Castillo A, Meseguer ML, Fonollosa Pla V, Gimenez BS, Colunga Arguelles D, Revilla Lopez E, et al. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. Sci Rep. 2022; 12(1). DOI:10.1038/s41598-022-09353-z.

Erton ZB, Sevim E, de Jesus GR, Cervera R, Ji L, Pengo V, et al. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry'). Lupus Sci Med. 2022; 9(1). DOI:10.1136/lupus-2021-000633.

Ruiz Irastorza G, Khamashta MA. What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?. Expert Rev Clin Immunol. 2022; 18(8): 1-3. DOI:10.1080/1744666X.2022.2090338.

Cardwell F, Elliott S, Chin R, Rowbottom L, St Pierre Y, Choi M, et al. Investigating the Determinants of Accessing Social and News Media and Experiencing Negative Impacts During COVID-19 in an International SLE Sample. J Rheumatol. 2022; 49(7): 816-816

Francisco Ugarte Gil M, Hanly J, Urowitz M, Gordon C, Bae S, Romero Diaz J, et al. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022; 81(11): 1541-1548. DOI:10.1136/ard-2022-222487.

Cardwell F, Elliott S, Choi M, Chin R, St Pierre Y, Rowbottom L, et al. Health Information Use by SLE Patients Pre and During COVID-19. J Rheumatol. 2022; 49(7): 816-817

Roa I, Soto Peleteiro A, Aberasturi Plata Y, Gendive Martin N. IgG4 related disease as a mimicker of metastatic pancreatic cancer. Rev Esp Enferm Dig. 2022; 114(8): 505-506. DOI:10.17235/reed.2022.8737/2022.

Erton ZB, K Leaf R, de Andrade D, Clarke AE, Tektonidou MG, Pengo V, et al. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). Lupus. 2022. DOI:10.1177/09612033221128742.

Cardwell FS, Elliott S, Chin R, St Pierre Y, Choi MY, Urowitz MB, et al. Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic. Lupus Sci Med. 2022; 9(1). DOI:10.1136/lupus-2022-000755.

Moreno Torres V, Martinez Urbistondo M, Gutierrez Rojas A, Castejon R, Sanchez E, Calderon Parra J, et al. Impact of severe infections in SLE: an observational study from the Spanish national registry. Lupus Sci Med. 2022; 9(1). DOI:10.1136/lupus-2022-000711.

Chighizola C, Pregnolato F, Andrade D, Tektonidou M, Sciascia S, Pengo V, et al. HYDROXYCHLOROQUINE REDUCES THE TITERS OF ANTI-DOMAIN 1 ANTIBODIES OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES: RESULTS FROM THE APS ACTION CLINICAL DATABASE AND REPOSITORY ("REGISTRY"). Ann Rheum Dis. 2022; 81: 484-485. DOI:10.1136/annrheumdis-2022-eular.4048.

Fonollosa A, Charcan I, Giralt L, Artaraz J, Soto A, Ruiz Arruza I, et al. Hyper-Reflective Outer Nuclear Layer (HONL) in Vogt-Koyanagi-Harada Disease and Sympathetic Ophthalmia. Ocul Immunol Inflamm. 2022. DOI:10.1080/09273948.2022.2134038.

Delgado P, Robles Á, Martínez López JA, Sáez Comet L, Rodríguez Almaraz E, Martínez Sánchez N et al. Management of Pregnancy in Patients with Systemic Lupus Erythematosus/Antiphospholipid Syndrome. Part 3: Childbirth. Puerperium. Breastfeeding Contraception. Newborn. Reumatol Clin. 2021; 17(4): 183-186. DOI:10.1016/j.reuma.2019.09.004.

Espinosa G, Galindo Izquierdo M, Marcos Puig B, Casellas Caro M, Delgado Beltrán P, Martínez López JA et al. Pregnancy Control in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Part 1: Infertility, Ovarian Preservation and Preconception Assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER). Reumatol Clin. 2021; 17(2): 61-66. DOI:10.1016/j.reuma.2019.09.002.

Rodríguez Almaraz E, Sáez Comet L, Casellas M, Delgado P, Ugarte A, Vela Casasempere P et al. Pregnancy Control in Patients with Systemic Lupus Erythematosus/Antiphospholipid Syndrome: Part 2: Pregnancy Follow-Up. Reumatol Clin. 2021; 17(3): 125-131. DOI:10.1016/j.reuma.2019.09.003.

Aranda Escano E, Prieto Calvo M, Perfecto Valero A, Ruiz Irastorza G, Gastaca Mateo M, Valdivieso Lopez A. Transplantation-mediated alloimmune thrombocytopenia successfully treated by retransplantation. Lupus. 2021; 30(4): 669-673. DOI:10.1177/0961203320983450.

Chew C, Reynolds JA, Lertratanakul A, Wu P, Urowitz M, Gladman DD et al. Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology (Oxford). 2021; 60(10): 4737-4747. DOI:10.1093/rheumatology/keab090.

Aringer M, Brinks R, Dorner T, Daikh D, Mosca M, Ramsey Goldman R et al. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Ann Rheum Dis. 2021; 80(6): 775-781. DOI:10.1136/annrheumdis-2020-219373.

Macia Rodriguez C, Alejandre de Ona A, Martin Iglesias D, Barrera Lopez L, Perez Sanz MT, Moreno Diaz J et al. Burn-out syndrome in Spanish internists during the COVID-19 outbreak and associated factors: a cross-sectional survey. Bmj Open. 2021; 11(2): 42966-42966. DOI:10.1136/bmjopen-2020-042966.

Ruiz Irastorza G. PREDNISONE IN SYSTEMIC LUPUS ERYTHEMATOSUS: TAPER QUICKLY, WITHDRAW SLOWLY. Rheumatology (Oxford). 2021; 60(12): 5489-5490. DOI:10.1093/rheumatology/keab347.

Ugarte A, Garcia de Bustos A, Ruiz Arruza I, Soto Peleteiro A, Martin Iglesias D, Gonzalez Echavarri C et al. ANTIPHOSPHOLIPID ANTIBODIES DO NOT PREDICT DAMAGE IN SLE PATIENTS IN THE XXI CENTURY. AN OBSERVATIONAL STUDY FROM THE LUPUS-CRUCES COHORT. Rheumatology (Oxford). 2021; 61(1): 249-257. DOI:10.1093/rheumatology/keab307.

Rubio Rivas M, Corbella X, Guillen Castillo A, Tolosa Vilella C, Colunga Arguelles D, Argibay A et al. Corrigendum to 'Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation' [AUTREV 19-5 (2020) 102507]. Autoimmun Rev. 2021; 20(5): 102793-102793. DOI:10.1016/j.autrev.2021.102793.

Mucke J, Alarcon Riquelme M, Andersen J, Aringer M, Bombardieri S, Brinks R et al. What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. Lupus Sci Med. 2021; 8(1). DOI:10.1136/lupus-2021-000506.

Hanly JG, Gordon C, Bae S, Romero Diaz J, Sanchez Guerrero J, Bernatsky S et al. Neuropsychiatric Events in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021; 73(12): 2293-2302. DOI:10.1002/art.41876.

Iniesta Arandia N, Espinosa G, Guillen Del Castillo A, Tolosa Vilella C, Colunga Arguelles D, Gonzalez de Echavarri Perez de Heredia C et al. Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature. JCR-J Clin Rheumatol. 2021. DOI:10.1097/RHU.0000000000001676.

Ruiz Irastorza G, Duena Bartolome L, Dunder S, Varona J, Gomez Carballo C, Dominguez Cainzos J et al. Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. Autoimmun Rev. 2021; 20(10): 102898-102898. DOI:10.1016/j.autrev.2021.102898.

Almeida Brasil C, Hanly J, Urowitz M, Clarke AE, Ramsey Goldman R, Gordon C et al. Flares after hydroxychloroquine reduction or discontinuation in a multinational inception cohort of systemic lupus. Pharmacoepidemiol Drug Saf. 2021; 30: 231-231

Almeida Brasil C, Hanly J, Urowitz M, Clarke AE, Ramsey Goldman R, Gordon C et al. Retinal toxicity in a multinational inception cohort of systemic lupus patients on hydroxychloroquine. Pharmacoepidemiol Drug Saf. 2021; 30: 325-325

de Azevedo Lopes E, Balbi GGM, Tektonidou MG, Pengo V, Sciascia S, Ugarte A et al. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. Adv Rheumatol. 2021; 61(1): 64-64. DOI:10.1186/s42358-021-00222-3.

Ugarte Gil MF, Hanly J, Urowitz MB, Gordon C, Bae SC, Romero Diaz J et al. LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT. Ann Rheum Dis. 2021; 80: 177-178. DOI:10.1136/annrheumdis-2021-eular.1133.

Ugarte Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reategui Sokolova C et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021; 8(1). DOI:10.1136/lupus-2021-000590.

Moreno Torres V, Tarin C, Ruiz Irastorza G, Castejon R, Gutierrez Rojas A, Royuela A et al. Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry. J Clin Med. 2021; 10(24). DOI:10.3390/jcm10245749.

Johnson SR, Gladman DD, Brunner HI, Isenberg D, Clarke AE, Barber MRW et al. Evaluating the construct of damage in systemic lupus erythematosus. Arthritis Care Res. 2021. DOI:10.1002/acr.24849.

Recio Barbero M, Cabezas Garduno J, Ruiz Irastorza G, Horrillo I, Meana JJ, Gonzalez Melero MI et al. Mood and anxiety disorders in Systemic Lupus Erythematosus: results and insights from the Lupus-Cruces cohort. Eur Neuropsychopharmacol. 2021; 53: 538-539. DOI:10.1016/j.euroneuro.2021.10.805.

Cardwell F, Elliott S, Chin R, Rowbottom L, St Pierre Y, Choi M et al. Determinants of Accessing Social and News Media and Experiencing Negative Impacts During COVID-19 in an International SLE Sample. Arthritis Rheumatol. 2021; 73: 1838-1840

Clarke A, Hanly J, St Pierre Y, Gordon C, Bae SC, Romero Diaz J et al. Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach. Arthritis Rheumatol. 2021; 73: 1826-1829

Cardwell F, Elliott S, Choi M, Chin R, Pierre YS, Rowbottom L et al. Health Information Use by SLE Patients Pre and During COVID-19. Arthritis Rheumatol. 2021; 73: 1823-1825

Choi M, Chen I, Clarke A, Fritzler M, Buhler K, Urowitz M et al. Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes. Arthritis Rheumatol. 2021; 73: 4038-4042

Brasil C, Hanly J, Urowitz M, Clarke A, Ramsey Goldman R, Gordon C et al. Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort. Arthritis Rheumatol. 2021; 73: 2002-2004

Ugarte Gil M, Ruiz Irastorza G, Gladman D, Urowitz M, Clarke A, Hanly J et al. Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort. Arthritis Rheumatol. 2021; 73: 2639-2641

Prevete I, Espinosa G, Bellisai F, Bortoluzzi A, Conti F, Fredi M, et al. Comparative study between two European inception cohorts of patients with early systemic lupus erythematosus. Clin Exp Rheumatol. 2020; 38(5): 925-932

Hanly JG, Urowitz MB, Gordon C, Bae SC, Romero Diaz J, Sanchez Guerrero J, et al. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis. 2020; 79(3): 356-362. DOI:10.1136/annrheumdis-2019-216150.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, et al. Prediction of damage accrual in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). Arthritis Rheumatol. 2020; 72(4): 658-666. DOI:10.1002/art.41144.

Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz MB, et al. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun. 2020; 106: 102340-102340. DOI:10.1016/j.jaut.2019.102340.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, et al. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2020; 72(1): 67-77. DOI:10.1002/art.41070.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, et al. Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. J Rheumatol. 2020; 47(1): 72-81. DOI:10.3899/jrheum.181338.

Suárez García I, Ruiz Algueró M, García Yubero C, Moreno C, Belza MJ, Estébanez M, et al. Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. J Antimicrob Chemother. 2020; 75(2): 466-472. DOI:10.1093/jac/dkz439.

Erdozain J, Pijoan J, Villar I, Nieto J, Ruiz Arruza I, Ruiz Irastorza G, et al. Ankle-brachial index and arterial vascular events in systemic lupus erythematosus patients: a 5-year prospective cohort. Clin Exp Rheumatol. 2020

Rubio Rivas M, Corbella X, Guillén Castillo A, Tolosa Vilella C, Colunga Argüelles D, Argibay A, et al. Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. Autoimmun Rev. 2020; 19(5): 102507-102507. DOI:10.1016/j.autrev.2020.102507.

Fanlo P, Espinosa G, Adan A, Fonollosa A, Segura A, en nombre del Grupo de Trabajo de Enfermedades Autoinmunes Sistémicas de la S, et al. Multidisciplinary care and units for uveitis in the internal medicine departments in Spain: Survey of the Systemic Autoimmune Diseases Group. Rev Clin Esp. 2020; 221(4): 221-225. DOI:10.1016/j.rce.2019.11.018.

Erdozain J, Pijoan J, Villar I, Nieto J, Ruiz Arruza I, Ruiz Irastorza G, et al. Ankle-brachial index and arterial vascular events in systemic lupus erythematosus patients: a 5-year prospective cohort. Clin Exp Rheumatol. 2020

Sainz Maza M, Adan A, Ruiz I, Beltran E, Yago I, Jimenez R, et al. Quality standards for Comprehensive Care Units for patients with uveitis of the Spanish Society of Ocular Inflammation (SEIOC). Med Clin. 2020; 156(2): 76-80. DOI:10.1016/j.medcli.2020.03.008.

Urowitz MB, Gladman DD, Farewell V, Su J, Romero Diaz J, Bae SC, et al. Accrual of atherosclerotic vascular events in a multicentre inception SLE cohort. Arthritis Rheumatol. 2020; 72(10): 1734-1740. DOI:10.1002/art.41392.

Ruiz Irastorza G, Ugarte A, Ruiz Arruza I, Khamashta M. Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus. 2020; 29(10): 1155-1167. DOI:10.1177/0961203320930099.

Mendel A, Bernatsky S, Askanase A, Bae S, Clarke AE, Costedoat Chalumeau N, et al. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Ann Rheum Dis. 2020; 80(2): 1-2. DOI:10.1136/annrheumdis-2020-218164.

Ruiz Irastorza G. Can we effectively treat lupus and reduce the side-effects of glucocorticoids?. Lancet Rheumatol. 2020; 2(1): 3-5. DOI:10.1016/S2665-9913(19)30132-8.

Zuily S, Clerc Urmes I, Bauman C, Andrade D, Sciascia S, Pengo V, et al. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus. 2020; 29(11): 1353-1363. DOI:10.1177/0961203320940776.

Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey Goldman R, et al. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Ann Rheum Dis. 2020; 79(10): 1333-1339. DOI:10.1136/annrheumdis-2020-217162.

Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, et al. Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. J Clin Med. 2020; 9(9). DOI:10.3390/jcm9092709.

Troncoso JA, Marhuenda AR, Villero FM, Hernandez FJG, Ballve AM, Castro A, et al. PULMONARY HYPERTENSION IN NEWLY DIAGNOSED SPANISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM THE RELES COHORT. Ann Rheum Dis. 2020; 79: 656-656. DOI:10.1136/annrheumdis-2020-eular.4906.

Johnson S, Brinks R, Costenbader K, Daikh D, Mosca M, Ramsey Goldman R, et al. PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES. Ann Rheum Dis. 2020; 79: 358-358. DOI:10.1136/annrheumdis-2020-eular.2324.

Troncoso JA, Marhuenda AR, Villero FM, Hernandez FJG, Ballve AM, Castro A, et al. CARDIAC INVOLVEMENT IN NEWLY DIAGNOSED SPANISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM THE RELES COHORT. Ann Rheum Dis. 2020; 79: 351-351. DOI:10.1136/annrheumdis-2020-eular.1633.

Bernatsky S, Ramsey Goldman R, Urowitz MB, Hanly JG, Gordon C, Petri MA, et al. Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications. Arthritis Care Res. 2020; 73(12): 1789-1795. DOI:10.1002/acr.24425.

Gonzalez A, Patier JL, Lopez Rodriguez M, del Castillo AG, Rubio Rivas M, Argibay A, et al. PREVALENCE AND RISK FACTORS FOR LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN SYSTEMIC SCLEROSIS: RESULTS FROM RESCLE REGISTRY. Ann Rheum Dis. 2020; 79: 1102-1103. DOI:10.1136/annrheumdis-2020-eular.963.

Ruiz Irastorza G, Martin Iglesias D, Soto Peleteiro A. Update on antimalarials and systemic lupus erythematosus. Curr Opin Rheumatol. 2020; 32(6): 572-582. DOI:10.1097/BOR.0000000000000743.

Vivero F, Iglesias DM, Vandale JM, Oliver M, Gandara V, Isnardi C, et al. PREDICTORS OF MORTALITY AND FUNCTIONAL IMPACT OF IMMUNOSUPPRESSIVE TREATMENT IN AUTOIMMUNE INTERSTITIAL LUNG DISEASE: A MULTICENTER STUDY. JCR-J Clin Rheumatol. 2020; 26: 16-16

Iniesta Arandia N, Espinosa G, del Castillo AG, Tolosa C, Lledoo GM, Arguuelles DC, et al. ANTI-PM/SCL ANTIBODIES IN SYSTEMIC SCLEROSIS: CLINICAL ASSOCIATIONS IN THE RESCLE COHORT. Ann Rheum Dis. 2020; 79: 1099-1100. DOI:10.1136/annrheumdis-2020-eular.3304.

Ruiz Irastorza G, Pijoan J, Bereciartua E, Dunder S, Dominguez J, Garcia Escudero P, et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. PLoS One. 2020; 15(9): 239401-239401. DOI:10.1371/journal.pone.0239401.

Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG, et al. Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. Arthritis Care Res. 2020; 74(2): 324-335. DOI:10.1002/acr.24468.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae S, Gordon C, et al. Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). Arthritis Care Res. 2020; 74(4): 638-647. DOI:10.1002/acr.24504.

Ruiz Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020; 59(Supplement_5): 69-81. DOI:10.1093/rheumatology/keaa403.

Martin Iglesias D, Artaraz J, Ruiz Irastorza G. Hydroxychloroquine Retinal Toxicity and Its Association with Dosage. J Rheumatol. 2020; 48(1): 150-150. DOI:10.3899/jrheum.200843.

Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, et al. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results from APS ACTION Clinical Database and Repository. J Rheumatol. 2020; 48(4): 541-547. DOI:10.3899/jrheum.200513.

Almeida Brasil C, Hanly J, Urowitz M, Clarke A, Ramsey Goldman R, Gordon C, et al. Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus. Arthritis Rheumatol. 2020; 72

Almeida Brasil C, Hanly J, Urowitz M, Clarke A, Ramsey Goldman R, Gordon C, et al. Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine. Arthritis Rheumatol. 2020; 72

Choi M, Fritzler M, Costenbader K, Urowitz M, Hanly J, Gordon C, et al. Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic Lupus Erythematosus Cohort. Arthritis Rheumatol. 2020; 72

Choi M, Clarke A, Costenbader K, Urowitz M, Hanly J, Gordon C, et al. Longitudinal Analysis of ANA Assay Performance in SLE from the SLICC Inception Cohort. Arthritis Rheumatol. 2020; 72

Recio Barbero M, Cabezas Garduno J, Zabala A, Ferreiro M, Ugarte A, Ruiz Irastorza G, et al. Neuropsychiatric symptoms in patients with systemic lupus erythematosus: prevalence and its impact on quality of life. Eur Neuropsychopharmacol. 2020; 40: 211-212. DOI:10.1016/j.euroneuro.2020.09.276.

Garcia Moyano M, Vivero Acosta F, Martin Iglesias D, Enghelmayer J, Lancellotti D, Gaser A, et al. Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD): Retrospective Multicentric Study. Eur Resp J. 2020; 56. DOI:10.1183/13993003.congress-2020.754.

Choi MY, Clarke AE, Pierre STY, Hanly JG, Urowitz MB, Romero Diaz J, et al. Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care Res. 2019; 71(7): 893-902. DOI:10.1002/acr.23712.

Goena C, Quintas L, Gonzalez De Echevarri C, Lluis I, Garcia R, Goiri JM, et al. Myocarditis in Antisynthetase Syndrome: an infrequent association. Eur J Heart Fail. 2019; 21: 500-500

Martin Iglesias D, Artaraz J, Fonollosa A, Ugarte A, Arteagabeitia A, Ruiz Irastorza G. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. Lupus. 2019; 28(4): 555-559. DOI:10.1177/0961203319829826.

Costedoat Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin Pharmacol Ther. 2019; 106(2): 374-382. DOI:10.1002/cpt.1194.

Mendel A, Bernatsky SB, Hanly JG, Urowitz MB, Clarke AE, Romero Diaz J, et al. Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Ann Rheum Dis. 2019; 78(7): 1010-1010. DOI:10.1136/annrheumdis-2018-214434.

Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Doerner T, Diamond B, et al. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(5): 634-640. DOI:10.1136/annrheumdis-2018-214685.

Wirestam L, Enocsson H, Skogh T, Padyukov L, Jonsen A, Urowitz MB, et al. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. J Rheumatol. 2019; 46(5): 492-500. DOI:10.3899/jrheum.180713.

Mendel A, Bernatsky S, Pineau CA, St Pierre Y, Hanly JG, Urowitz MB, et al. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology (Oxford). 2019; 58(7): 1259-1267. DOI:10.1093/rheumatology/kez014.

Erdozain AM, Brocos Mosquera I, Gabilondo AM, Meana JJ, Callado LF. Differential alpha(2A)- and alpha(2C)-adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex. J Psychopharmacol. 2019; 33(2): 244-249. DOI:10.1177/0269881118798612.

Uthman I, Noureldine MH, Ruiz Irastorza G, Khamashta M. Management of antiphospholipid syndrome. Ann Rheum Dis. 2019; 78(2): 155-161. DOI:10.1136/annrheumdis-2018-213846.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019; 71(9): 1400-1412. DOI:10.1002/art.40930.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae S, Gordon C, et al. Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019; 71(8): 1297-1307. DOI:10.1002/art.40859.

Hanly J, Li Q, Li SU, Urowitz MB, Gordon C, Bae S, et al. NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY. Ann Rheum Dis. 2019; 78(2): 206-207. DOI:10.1136/annrheumdis-2019-eular.1820.

Ruiz Irastorza G, Ruiz Estevez B, Lazaro E, Ruiz Arruza I, Duffau P, Martin Cascon M, et al. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmun Rev. 2019; 18(9): 102359-102359. DOI:10.1016/j.autrev.2019.102359.

Hanly JG, Li Q, Su LI, Urowitz MB, Gordon C, Bae S, et al. Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2019; 71(2): 281-289. DOI:10.1002/art.40764.

Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, et al. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. Thromb Res. 2019; 175: 32-36. DOI:10.1016/j.thromres.2019.01.010.

Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, et al. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. Arthritis Care Res. 2019; 71(1): 134-141. DOI:10.1002/acr.23584.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(9): 1151-1159. DOI:10.1136/annrheumdis-2018-214819.

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019; 78(10): 1296-1304. DOI:10.1136/annrheumdis-2019-215213.

Sevim E, de Jesus GR, Ji L, Ugarte A, Pengo V, Cervera R, et al. Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from APS ACTION Registry. Lupus. 2019; 28: 16-16

Brocos Mosquera I, Erdozain AM, Meana JJ, Callado LF, Diez Alarcia R. Alterations in alpha 2A-adrenoceptor mediated G-protein signalling in postmortem prefrontal cortex of schizophrenia subjects. Eur Neuropsychopharmacol. 2019; 29(2): 638-639. DOI:10.1016/j.euroneuro.2019.01.011.

Mongredien R, Erdozain AM, Dumas S, Cutando L, Nunez del Moral A, Puighermanal E, et al. Cartography of hevin-expressing cells in the adult brain reveals prominent expression in astrocytes and parvalbumin neurons. Brain Struct Funct. 2019; 224(3): 1219-1244. DOI:10.1007/s00429-019-01831-x.

Radin M, Tektonidou MG, Ji L, de Jesus GR, Branch DW, Fortin PR, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin Arthritis Rheum. 2019; 49(3): 464-468. DOI:10.1016/j.semarthrit.2019.04.009.

Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, et al. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. J Thromb Haemost. 2019; 17(12): 2069-2080. DOI:10.1111/jth.14596.

Barber MRW, Hanly JG, Su L, Urowitz MB, Pierre STY, Romero Diaz J, et al. Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach. Arthritis Care Res. 2019; 72(12): 1800-1808. DOI:10.1002/acr.24092.

Moreno Díaz J, Aranda Sánchez M, González Munera A, Demelo Rodríguez P, Martín Iglesias D, Macía Rodíguez C, et al. Getting to know internal medicine mentors: new training requirements. Rev Clin Esp. 2019; 219(2): 67-72. DOI:10.1016/j.rce.2018.06.009.

Macía Rodríguez C, López Reboiro ML, Martín Iglesias D, González Munera A, Moreno Diaz J, Montaño Martínez A, et al. Fifth-year internal medicine residents in Spain: A survey on education, assessment of competencies and job perspectives. Rev Clin Esp. 2019; 219(2): 61-66. DOI:10.1016/j.rce.2018.05.007.

de Jesus GR, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A, et al. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG. 2019; 126(5): 656-661. DOI:10.1111/1471-0528.15469.

Aringer M, Brinks R, Costenbader K, Daikh D, Boumpas D, Jayne D, et al. Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease. Arthritis Rheumatol. 2019; 71(10)

Bernatsky S, Ramsey Goldman R, Urowitz M, Hanly J, Gordon C, Petri M, et al. Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications. Arthritis Rheumatol. 2019; 71(10)

Choi M, Barber M, Fritzler M, Hanly JG, Urowitz M, St Pierre Y, et al. Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort?. Arthritis Rheumatol. 2019; 71(10)

Mak A, L Cheung MW, Leong WYJ, Dharmadhikari B, Kow NY, Petri M, et al. Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus - Meta-analyses of Observational Studies Published Between 1979 and 2018. Arthritis Rheumatol. 2019; 71(10)

Hanly JG, Li Q, Su LI, Urowitz M, Gordon C, Bae S, et al. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study. Arthritis Rheumatol. 2019; 71(10)

Legge A, Kirkland S, Rockwood K, Andreou P, Bae S, Gordon C, et al. Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index. Arthritis Rheumatol. 2019; 71(10)

Urowitz M, Gladman D, Su J, Farewell V, Sanchez Guerrero J, Romero Diaz J, et al. Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort. Arthritis Rheumatol. 2019; 71(10)

Costedoat Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin Pharmacol Ther. 2018; 103(6): 1074-1082. DOI:10.1002/cpt.885.

Ruiz Arruza I, Lozano J, Cabezas Rodriguez I, Medina JA, Ugarte A, Erdozain JG, et al. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. Arthritis Care Res. 2018; 70(4): 582-591. DOI:10.1002/acr.23322.

Barber MRW, Hanly JG, Su L, Urowitz MB, Pierre YS, Romero Diaz J, et al. Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care Res. 2018; 70(9): 1294-1302. DOI:10.1002/acr.23480.

Gonzalez Echavarri C, Capdevila O, Espinosa G, Suarez S, Marin Ballve A, Gonzalez Leon R, et al. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus. 2018; 27(14): 2253-2261. DOI:10.1177/0961203318811598.

Aringer M, Costenbader K, Brinks R, Boumpas D, Daikh D, Jayne D, et al. Validation of New Systemic Lupus Erythematosus Classification Criteria. Arthritis Rheumatol. 2018; 70(9)

Hanly JG, Li QJ, Su L, Urowitz M, Gordon C, Bae SC, et al. Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study. Arthritis Rheumatol. 2018; 70(9)

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, et al. Construction and Validation of a Frailty Index As a Novel Health Measure in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018; 70(9)

Sevim E, Andrade D, Banzato A, Tektonidou M, Ugarte A, Chighizola CB, et al. Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry"). Arthritis Rheumatol. 2018; 70(9)

Ugarte A, Danza A, Ruiz Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol. 2018; 30(5): 482-489. DOI:10.1097/BOR.0000000000000527.

Ugarte A, Porta S, Rios R, Martinez Zapico A, Ortego Centeno N, Agesta N, et al. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Lupus. 2018; 27(10): 1718-1722. DOI:10.1177/0961203318768877.

Berasategui B, Fonollosa A, Artaraz J, Ruiz Arruza I, Rios J, Matas J, et al. Behavior of hyperreflective foci in non-infectious uveitic macular edema, a 12-month follow-up prospective study. BMC Ophthalmol. 2018; 18. DOI:10.1186/s12886-018-0848-5.

Zabala A, Salgueiro M, Saez Atxukarro O, Ballesteros J, Ruiz Irastorza G, Segarra R. Cognitive Impairment in Patients With Neuropsychiatric and Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. J Int Neuropsychol Soc. 2018; 24(6): 629-639. DOI:10.1017/S1355617718000073.

Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz Irastorza G, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018; 4. DOI:10.1038/nrdp.2017.103.

Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, et al. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford). 2018; 57(4): 677-687. DOI:10.1093/rheumatology/kex444.

Sevim E, Unlu O, Andrade D, Banzato A, Tektonidou M, Ugarte A, et al. First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry"). Arthritis Rheumatol. 2018; 70(9)

Sevim E, Zisa DF, Andrade D, Pengo V, Tektonidou M, Ugarte A, et al. Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry"). Arthritis Rheumatol. 2018; 70(9)

Ruiz Irastorza G, Ugarte A, Ruiz Arruza I, Erdozain JG, Gonzalez Echavarri C, Soto A. Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018; 57(8): 1501-1502. DOI:10.1093/rheumatology/key168.

Hanly JG, Li QJ, Su L, Urowitz MB, Gordon C, Bae SC, et al. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care Res. 2018; 70(10): 1478-1487. DOI:10.1002/acr.23509.

Isenberg D, Sturgess J, Allen E, Aranow C, Askanase A, Sang Cheol B, et al. Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care Res. 2018; 70(1): 98-103. DOI:10.1002/acr.23252.

Sanchez Cano D, Ortego Centeno N, Callejas JL, Pla VF, Rios Fernandez R, Tolosa Vilella C, et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int. 2018; 38(3): 363-374. DOI:10.1007/s00296-017-3916-x.

Rubio Rivas M, Corbella X, Pestana Fernandez M, Tolosa Vilella C, Guillen del Castillo A, Colunga Arguelles D, et al. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clin Rheumatol. 2018; 37(4): 999-1009. DOI:10.1007/s10067-017-3936-7.

Mari Alfonso B, Simeon Aznar CP, Guillen Del Castillo A, Rubio Rivas M, Trapiella Martinez L, Todoli Parra JA, et al. Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. Semin Arthritis Rheum. 2018; 47(6): 849-857. DOI:10.1016/j.semarthrit.2017.10.004.

Gomez Rubio J, Barcena Atalaya AB, Ruiz Irastorzac G. Extraparotidal low grade follicular lymphoma associated with primary Sjogren's syndrome. Med Clin. 2018; 150(5): 204-205. DOI:10.1016/j.medcli.2017.06.056.

Marquez A, Kerick M, Zhernakova A, Gutierrez Achury J, Chen W, Onengut Gumuscu S, et al. Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. Genome Med. 2018; 10. DOI:10.1186/s13073-018-0604-8.

Rodríguez Carballeira M, Solans R, Larrañaga JR, García Hernández FJ, Rios Fernández R, Nieto J, et al. Venous thrombosis and relapses in patients with Behçet's disease. Descriptive analysis from Spanish network of Behçet's disease (REGEB cohort). Clin Exp Rheumatol. 2018; 36(6 Suppl 115): 40-44

Tani C, Elefante E, Martin Cascón M, Belhocine M, Lavilla Olleros C, Vagelli R, et al. Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres. Lupus Sci Med. 2018; 5(1). DOI:10.1136/lupus-2018-000274.

Márquez A, Cordero Coma M, Martín Villa JM, Gorroño Echebarría MB, Blanco R, Díaz Valle D, et al. New insights into the genetic component of non-infectious uveitis through an Immunochip strategy. J Med Genet. 2017; 54(1): 38-46. DOI:10.1136/jmedgenet-2016-104144.

Bernatsky S, Ramsey Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PF, et al. Breast cancer in systemic lupus. Lupus. 2017; 26(3): 311-315. DOI:10.1177/0961203316664595.

Canora J, García M, Mitjavila F, Espinosa G, Suárez S, González León R, et al. Clinical characteristics during diagnosis of a prospective cohort of patients with systemic lupus erythematosus treated in Spanish Departments of Internal Medicine: The RELES study. Rev Clin Esp. 2017; 217(1): 7-14. DOI:10.1016/j.rce.2016.09.006.

Amengual O, Forastiero R, Sugiura Ogasawara M, Otomo K, Oku K, Favas C, et al. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus. 2017; 26(3): 266-276. DOI:10.1177/0961203316660203.

Erdozain JG, Villar I, Nieto J, Ruiz Arruza I, Ruiz Irastorza G. Predictors of peripheral arterial disease in SLE change with patient's age. Lupus Sci Med. 2017; 4(1). DOI:10.1136/lupus-2016-000190.

Cabezón I, Barreiro G, Egurbide MV. Parsonage-Turner syndrome: A case report. Reumatol Clin. 2017; 13(1): 60-61. DOI:10.1016/j.reuma.2016.03.001.

Bernatsky S, Urowitz M, Hanly JG, Clarke AE, Fritzler MJ, Gordon C, et al. Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor. Arthritis Rheumatol. 2017; 69(10)

Sevim E, Andrade D, Banzato A, Branch DW, Cervera R, de Jesus GR, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Analysis: Pregnancy Outcomes Since Inception. Arthritis Rheumatol. 2017; 69(10)

Tani C, Martin Cascon M, Belhocine M, Vagelli R, Stagnaro C, Ruiz Irastorza G, et al. Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers. Arthritis Rheumatol. 2017; 69(10)

Tedeschi SK, Johnson S, Boumpas D, Daikh DI, Diamond B, Doerner T, et al. A Multicriteria Decision Analysis for the Development of New Systemic Lupus Erythematosus Classification Criteria. Arthritis Rheumatol. 2017; 69(10)

Unlu O, Andrade D, Banzato A, Branch DW, Fortin PR, Gerosa M, et al. Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository ("Registry") Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up. Arthritis Rheumatol. 2017; 69(10)

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero Diaz J, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017; 26(10): 1051-1059. DOI:10.1177/0961203317692437.

Bernatsky S, Urowitz M, Hanly J, Clarke A, Gordon C, Romera Diaz J, et al. Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort. J Rheumatol. 2017; 44(6): 857-858

Ruiz Irastorza G, Ugarte A, Terrier CSP, Lazaro E, Iza A, Couzi L, et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017; 16(8): 826-832. DOI:10.1016/j.autrev.2017.05.017.

Tedeschi S, Johnson S, Boumpas D, Daikh D, Diamond B, Dorner T, et al. MULTICRITERIA DECISION ANALYSIS FOR DEVELOPING NEW CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis. 2017; 76(2): 50-50. DOI:10.1136/annrheumdis-2017-eular.5464.

Erdozain JG, Villar I, Nieto J, Ruiz Arruza I, Pijoan JI, Ruiz Lrastorza G. PREDICTORS OF ARTERIAL VASCULAR EVENTS IN A COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis. 2017; 76(2): 593-593. DOI:10.1136/annrheumdis-2017-eular.3013.

Trapiella Martinez L, Diaz Lopez JB, Caminal Montero L, Tolosa Vilella C, Castillo A, Colunga Arguelles D, et al. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort. Autoimmun Rev. 2017; 16(8): 796-802. DOI:10.1016/j.autrev.2017.05.013.

Ferreira I, Croca S, Raimondo MG, Matharu M, Miller S, Giles I, et al. Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Res Ther. 2017; 19(1): 287-287. DOI:10.1186/s13075-017-1495-6.

Freire M, Rivera A, Sopena B, Vilella CT, Guillen Del Castillo A, Arguelles DC, et al. Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review. Clin Exp Rheumatol. 2017; 35(4): 89-97

Arandia NI, Simeon Aznar CP, del Castillo AG, Arguelles DC, Rubio Rivas M, Martinez LT, et al. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. Clin Exp Rheumatol. 2017; 35(4): 98-105

Rubio Rivas M, Simeon Aznar CP, Velasco C, Mari Alfonso B, Espinosa G, Corbella X, et al. Changes in the pattern of death of 987 patients with systemic sclerosis; from 1990 to 2009 from the nationwide Spanish Scleroderma Registry; (RESCLE). Clin Exp Rheumatol. 2017; 35(4): 40-47

Jackson WG, Oromendia C, Unlu O, Erkan D, DeSancho MT, Antiphospholipid Syndrome Alliance for Clinical Trials and International N. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017; 1(25): 2320-2324. DOI:10.1182/bloodadvances.2017008185.

Bossini Castillo L, Campillo Davó D, López Isac E, Carmona FD, Simeon CP, Carreira P, et al. An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. J Rheumatol. 2017; 44(10): 1453-1457. DOI:10.3899/jrheum.161369.

Fonollosa A, Martinez Indart L, Artaraz J, Martinez Berriotxoa A, Agirrebengoa K, Garcia M, et al. Clinical Manifestations and Outcomes of Syphilis-associated Uveitis in Northern Spain. Ocul Immunol Inflamm. 2016; 24(2): 147-152. DOI:10.3109/09273948.2014.943349.

Fonollosa A, Llorenç V, Artaraz J, Jimenez B, Ruiz Arruza I, Agirrebengoa K, et al. SAFETY AND EFFICACY OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN THE MANAGEMENT OF MACULAR EDEMA SECONDARY TO INFECTIOUS UVEITIS. Retin-J Retin Vitr Dis. 2016; 36(9): 1778-1785. DOI:10.1097/IAE.0000000000001001.

Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016; 2: 16039-16039. DOI:10.1038/nrdp.2016.39.

Ruiz Irastorza G, Garcia M, Espinosa G, Cabezas Rodriguez I, Mitjavila F, Gonzalez Leon R, et al. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2016; 34(3): 466-472

Legault KJ, Ugarte A, Crowther MA, Ruiz Irastorza G. Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?. Curr Rheumatol Rep. 2016; 18(5): 26-26. DOI:10.1007/s11926-016-0573-0.

Skorpen CG, Hoeltzenbein M, Tincani A, Fischer Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016; 75(5): 795-810. DOI:10.1136/annrheumdis-2015-208840.

Gonzalez Echavarri C, Ugarte A, Ruiz Irastorza G. Rituximab-refractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol. 2016; 34(2): 355-356

Danza A, Grana D, Goni M, Vargas A, Ruiz Irastorza G. Hydroxychloroquine for autoimmune diseases. Rev Medica Chile. 2016; 144(2): 232-240. DOI:10.4067/S0034-98872016000200012.

Hanly JG, O'Keeffe AG, Su LI, Urowitz MB, Romero Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016; 55(2): 252-262. DOI:10.1093/rheumatology/kev311.

Sciascia S, Branch DW, Levy RA, Middeldorp S, Pavord S, Roccatello D, et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Thromb Haemost. 2016; 115(2): 285-290. DOI:10.1160/TH15-06-0491.

Ochoa E, Iriondo M, Manzano C, Fullaondo A, Villar I, Ruiz Irastorza G, et al. LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers. PLoS One. 2016; 11(1). DOI:10.1371/journal.pone.0146990.

Danza A, Ruiz Irastorza G, Khamashta M. Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts. Med Clin. 2016; 147(7): 306-312. DOI:10.1016/j.medcli.2016.03.019.

Ugarte A, Ruiz Irastorza G. SLE: the changing prognosis. Lupus. 2016; 25(12): 1285-1287. DOI:10.1177/0961203316652948.

Fonollosa A, Valsero S, Artaraz J, Ruiz Arruza I. Dexamethasone intravitreal implants in the management of tubercular multifocal serpiginoid choroiditis. J Ophthalmic Inflamm Infect. 2016; 6. DOI:10.1186/s12348-016-0101-4.

Hanly JG, Su LI, Urowitz MB, Romero Diaz J, Gordon C, Bae S, et al. A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis Rheumatol. 2016; 68(8): 1932-1944. DOI:10.1002/art.39674.

del Pino Sedeno T, Trujillo Martin MM, Ruiz Irastorza G, Cuellar Pompa L, de Pascual Medina AM, Serrano Aguilar P, et al. Effectiveness of Nonpharmacologic Interventions for Decreasing Fatigue in Adults With Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res. 2016; 68(1): 141-148. DOI:10.1002/acr.22675.

Vivero F, Gonzalez Echavarri C, Ruiz Estevez B, Maderuelo I, Ruiz Irastorza G. Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. Autoimmun Rev. 2016; 15(12): 1134-1140. DOI:10.1016/j.autrev.2016.09.007.

Urowitz MB, Gladman DD, Anderson NM, Su J, Romero Diaz J, Bae SC, et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med. 2016; 3(1). DOI:10.1136/lupus-2015-000143.

Trujillo Martín MM, Rúa Figueroa Fernández de Larrinoa I, Ruíz Irastorza G, Pego Reigosa JM, Sabio Sánchez JM, Serrano Aguilar P, et al. Guía de práctica clínica para el lupus eritematoso sistémico: recomendaciones para el abordaje clínico general. Med Clin. 2016; 146(9). DOI:10.1016/j.medcli.2016.01.013.

Ruiz Irastorza G, Garcia M, Espinosa G, Caminal L, Mitjavila F, González León R, et al. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med. 2016; 3(1). DOI:10.1136/lupus-2016-000153.

Porta S, Martinez A, Ugarte A, Rios R, Ortego N, Ruiz Irastorza G. RESPONSE TO A COMBINED HYDROXYCHLOROQUINE-QUINACRINE TREATMENT IN SLE WITH CUTANEOUS AND/OR JOINT DISEASE. Clin Exp Rheumatol. 2016; 34(4): 14-14

Tolosa Vilella C, Lluisa Morera Morales M, Pilar Simeon Aznar C, Mari Alfonso B, Colunga Arguelles D, Callejas Rubio JL, et al. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. Semin Arthritis Rheum. 2016; 46(2): 200-208. DOI:10.1016/j.semarthrit.2016.04.007.

Del Pozo R, Quezada Loaiza CA, Barbera JA, Dos Subira L, Molina Ferragut L, Castillo Palma MJ, et al. Influence of age at diagnosis in the prognostic evaluation of patients with idiopathic pulmonary arterial hypertension and associated to connective tissue disease: insights of Spanish Registry (REHAP). Eur Heart J. 2016; 37(1): 363-363

Costedoat Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. ADHERENCE TO HYDROXYCHLOROQUINE AS ASSESSED BY MEASUREMENTS OF DRUG AND METABOLITE BLOOD LEVELS IN AN INTERNATIONAL PROSPECTIVE STUDY OF SLE PATIENTS IN FLARE. Clin Exp Rheumatol. 2016; 34(4): 41-41

Rydén Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal Montero L, Castro A, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016; 3(1). DOI:10.1136/lupus-2016-000163.

Alberich S, Barbeito S, Gonzalez Ortega I, Ugarte A, Vega P, Ruiz de Azua S, et al. Psychometric properties and validation of a four-item version of the Strauss-Carpenter scale in bipolar disorder. Int J Bipolar Disord. 2016; 4. DOI:10.1186/s40345-016-0063-3.

Lopez Isac E, Martin J, Assassi S, Simeon CP, Carreira P, Ortego Centeno N, et al. IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. Arthritis Rheumatol. 2016; 68(9): 2338-2344. DOI:10.1002/art.39730.

Lopez Isac E, Campillo Davo D, Bossini Castillo L, Guerra SG, Assassi S, Pilar Simeon C, et al. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. Ann Rheum Dis. 2016; 75(8): 1521-1526. DOI:10.1136/annrheumdis-2015-208154.

Brito Zeron P, Bosch X, Perez Lis M, Perez Alvarez R, Fraile G, Gheitasi H, et al. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Semin Arthritis Rheum. 2016; 45(4): 391-399. DOI:10.1016/j.semarthrit.2015.07.004.

Rodriguez Huerta MD, Trujillo Martin MM, Rua Figueroa I, Cuellar Pompa L, Quiros Lopez R, Serrano Aguilar P, et al. Healthy lifestyle habits for patients with systemic lupus erythematosus: A systemic review. Semin Arthritis Rheum. 2016; 45(4): 463-470. DOI:10.1016/j.semarthrit.2015.09.003.

Dominguez Rubio R, Martinez A, Poza J, Garcia Bragado F, Jerico I, van der Ven P, et al. Intranuclear protein aggregation in myofibrillar myopathies. Neuromusc Disord. 2016; 26(2): 191-191. DOI:10.1016/j.nmd.2016.06.381.

Ugarte A, Ruiz Irastorza G. Rituximab in antiphospholipid syndrome: Always, never, sometimes?. Med Clin. 2015; 144(3): 115-117. DOI:10.1016/j.medcli.2014.04.014.

Gonzalez Echavarri C, Villar I, Ugarte A, Larrieta R, Ruiz Irastorza G. Prevalence and Significance of Persistently Positive Antiphospholipid Antibodies in Women with Preeclampsia. J Rheumatol. 2015; 42(2): 210-213. DOI:10.3899/jrheum.140737.

Orbai A, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcon GS, et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus. 2015; 24(1): 42-49. DOI:10.1177/0961203314547791.

Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015; 74(9): 1706-1713. DOI:10.1136/annrheumdis-2013-205171.

Ostensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse MEB, et al. State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmun Rev. 2015; 14(5): 376-386. DOI:10.1016/j.autrev.2014.12.011.

Gabriel Erdozain J, Ruiz Irastorza G. Metabolic syndrome in patients with systemic lupus erythematosus: Causes and consequences. Med Clin. 2015; 144(7): 309-311. DOI:10.1016/j.medcli.2014.09.011.

Mucientes A, Marquez A, Cordero Coma M, Manuel Martin Villa J, Begona Gorrono Echebarria M, Blanco R, et al. Specific association of IL17A genetic variants with panuveitis. Br J Ophthalmol. 2015; 99(4): 566-570. DOI:10.1136/bjophthalmol-2014-306106.

Les I, Pijoan JI, Rodriguez Alvarez R, Ruiz Irastorza G, Martinez Berriotxoa A. Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Clin Exp Rheumatol. 2015; 33(2): 90-97

Bustillo M, Segarra R, Querejeta I, Gonzalez Pinto A, Mentxaka O, Carton J, et al. Is therapeutic drug monitoring of olanzapine a useful clinical tool in first-episode psychosis patients?. Eur Neuropsychopharmacol. 2015; 25(1): 63-64

Ruiz Arruza I, Barbosa C, Ugarte A, Ruiz Lrastorza G. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015; 14(10): 875-879. DOI:10.1016/j.autrev.2015.05.011.

Ochoa E, Martin J-, Assassi S, Beretta L, Carreira P, Guillen A, et al. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clin Exp Rheumatol. 2015; 33(4): 31-35

Saez Comet L, Pilar Simeon Aznar C, Perez Conesa M, Vallejo Rodriguez C, Tolosa Vilella C, Iniesta Arandia N, et al. Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort. J Rheumatol. 2015; 42(12): 2327-2331. DOI:10.3899/jrheum.150144.

Merino M, Marques M, Egurbide M, Romo M, Rodriguez I, Garcia M, et al. DEPLOYING INTEGRATED CARE MODELS FOR FRAIL ELDERLY PATIENTS. Int J Integr Care. 2015; 15(S)

Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae S, et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2015; 74(8): 1530-1536. DOI:10.1136/annrheumdis-2013-203933.

Astigarraga I, Ceberio L, Gondra A, Adan R, Echebarria A, Canovas A, et al. LANGERHANS CELL HISTIOCYTOSIS (LCH) IN CHILDREN AND ADULTS: A COMPARATIVE STUDY OF 40 CASES. Pediatr Blood Cancer. 2015; 62(4): 299-300

Hanly JG, Su LI, Urowitz MB, Romero Diaz J, Gordon C, Bae S, et al. Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2015; 67(7): 1837-1847. DOI:10.1002/art.39111.

Garcia Gomez M, Guio L, Luis Hernandez J, Vilar B, Ignacio Pijoan J, Miguel Montejo J. Bacteraemia due to extended-spectrum beta-lactamases (ESBL) and other beta-lactamases (ampC and carbapenemase) producing Enterobacteriaceae: association with health-care and cancer. Rev Esp Quimioter. 2015; 28(5): 256-262

Leon Rodriguez DA, Serrano Lopera A, Cordero Coma M, Marquez A, Fonollosa A, Ruiz Arruza I, et al. Study of association of CTLA4 gene variants to non-anterior uveitis. Tissue Antigens. 2015; 86(5): 373-376. DOI:10.1111/tan.12668.

Del Pozo R, Blanco I, Quezada CA, Lopez Reyes R, Egurbide Arberas V, Cremer Luengos D, et al. Factors associated with operability of chronic thromboembolic pulmonary hypertension: insights of Spanish registry (REHAP). Eur Heart J. 2015; 36(1): 628-628

Simeon Aznar CP, Fonollosa Pla V, Tolosa Vilella C, Espinosa Garriga G, Campillo Grau M, Ramos Casals M, et al. Registry of the Spanish Network for Systemic Sclerosis Survival, Prognostic Factors, and Causes of Death. Medicine (Baltimore). 2015; 94(43). DOI:10.1097/MD.0000000000001728.

Hanly JG, Su LI, Urowitz M, Romero Diaz J, Gordon C, Bae S, et al. A Longitudinal Analysis of Change in Lupus Nephritis in an International Inception Cohort Using a Multistate Markov Model Approach. Arthritis Rheumatol. 2015; 67(10)

Sturgess J, Allan E, Isenberg DA, Aranow C, Aringer M, Askanase A, et al. A Paper Patient-Based Flare Study in SLE. Arthritis Rheumatol. 2015; 67(10)

Hanly JG, Li Q, Su LI, Urowitz M, Romero Diaz J, Gordon C, et al. The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study. Arthritis Rheumatol. 2015; 67(10)

Barber M, Hanly JG, O'Keeffe A, Su LI, Urowitz M, St Pierre Y, et al. Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis. Arthritis Rheumatol. 2015; 67(10)

Choi M, Hanly JG, Urowitz M, Romero Diaz J, Gordon C, Bae S, et al. The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015; 67(10)

Serrano Aguilar P, Trujillo Martin Mdel M, Pérez de la Rosa A, Cuellar Pompa L, Saavedra Medina H, Linertova R, et al. Patient participation in a Clinical Guideline Development for Systemic Lupus Erythematosus. Patient Educ Couns. 2015; 98(9): 1156-1163. DOI:10.1016/j.pec.2015.05.022.

RUIZ IRASTORZA G. Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico. Guías de Práctica Clínica. 2015

Arana B, Fonollosa A, Artaraz J, Martinez Berriotxoa A, Martinez Alday N. Macular hole secondary to toxoplasmic retinochoroiditis. Int Ophthalmol. 2014; 34(1): 141-143. DOI:10.1007/s10792-013-9754-2.

Ruiz Irastorza G, Danza A, Perales I, Villar I, Garcia M, Delgado S, et al. Prednisone in lupus nephritis: How much is enough?. Autoimmun Rev. 2014; 13(2): 206-214. DOI:10.1016/j.autrev.2013.10.013.

Erdozain JG, Villar I, Nieto J, Ruiz Irastorza G. Peripheral Arterial Disease in Systemic Lupus Erythematosus: Prevalence and Risk Factors. J Rheumatol. 2014; 41(2): 310-317. DOI:10.3899/jrheum.130817.

Bernatsky S, Ramsey Goldman R, Joseph L, Boivin J, Costenbader KH, Urowitz MB, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014; 73(1): 138-142. DOI:10.1136/annrheumdis-2012-202099.

Gonzalez Echavarri C, Pernas B, Ugarte A, Ruiz Irastorza G. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone. Lupus. 2014; 23(3): 323-326. DOI:10.1177/0961203314520842.

Alba MA, Velasco C, Pilar Simeon C, Fonollosa V, Trapiella L, Victoria Egurbide M, et al. Early- versus Late-Onset Systemic Sclerosis Differences in Clinical Presentation and Outcome in 1037 Patients. Medicine (Baltimore). 2014; 93(2): 73-81. DOI:10.1097/MD.0000000000000018.

Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L, et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford). 2014; 53(2): 275-284. DOI:10.1093/rheumatology/ket313.

Lopez Isac E, Bossini Castillo L, Simeon CP, Victoria Egurbide M, Jose Alegre Sancho J, Luis Callejas J, et al. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Res Ther. 2014; 16(1). DOI:10.1186/ar4432.

Ruiz Arruza I, Ugarte A, Cabezas Rodriguez I, Medina J, Moran M, Ruiz Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014; 53(8): 1470-1476. DOI:10.1093/rheumatology/keu148.

Mild M, Wallace DJ, Clarke AE, Bernatsky SR, Peschken C, Jacobsen S, et al. Patient characteristics in the Prospective International Register of Biologics in SLE (IRBIS-II): year 1 data. Scand J Rheumatol. 2014; 43(127): 61-62

Erdozain JG, Villar I, Nieto J, Ruiz Irastorza G. Dr. Erdozain, et al reply. J Rheumatol. 2014; 41(10): 2086-2086. DOI:10.3899/jrheum.140442.

Hanly JG, O'Keeffe A, Su LI, Urowitz MB, Romero Diaz J, Gordon C, et al. Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study. Arthritis Rheumatol. 2014; 66(10, SI): 428-429

Hanly JG, Su LI, Urowitz M, Romero Diaz J, Gordon C, Bae S, et al. Mood Disorders in Systemic Lupus Erythematousus (SLE): Results from an International, Inception Cohort Study. Arthritis Rheumatol. 2014; 66(10, SI): 1158-1159

Erkan D, Andrade D, Tektonidou M, Ugarte A, Banzato A, Tincani A, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Initial Analysis. Arthritis Rheumatol. 2014; 66(10, SI): 1253-1254

Rodriguez Alvarez R, Goikoetxea J, Garcia M, Figueras Y, Hernandez L, Montejo M. Endovascular infections by Campylobacter: with regard to two cases. Rev Esp Quimioter. 2014; 27(2): 127-129

Martin J, Ochoa E, Ezequiel Martin J, Assassi S, Beretta L, Caireira P, et al. Systemic Sclerosis Patients with Antitopoisomerase Antibodies Showed Significant Association with CCR6 Polymorphisms. Arthritis Rheumatol. 2014; 66(10, SI): 328-328

Rodriguez Carballeira M, Alba MA, Solans Laque R, Castillo MJ, Rios Fernandez R, Larranaga JR, et al. Registry of the Spanish network of Behcet's disease: a descriptive analysis of 496 patients. Clin Exp Rheumatol. 2014; 32(4): 33-39

Amenqual O, Forastiero R, Sugiura Ogasawara M, Oku K, Otomo K, Alves J, et al. INTERNATIONAL MULTI-CENTRE STUDY TO EVALUATE THE CLINICAL SIGNIFICANCE OF PHOSPHATIDYLSERINE-DEPENDENT ANTIPROTHROMBIN ANTIBODIES FOR THE DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME. Ann Rheum Dis. 2014; 73(2): 662-663. DOI:10.1136/annrheumdis-2014-eular.2426.

Saez Comet L, Perez Conesa M, Vallejo Rodriguez C, Fonollosa Pla V, Colunga Arguelles D, Egurbide Arberas MV, et al. COMPARISON OF ACR 1980'S AND ACR/EULAR 2013'S SYSTEMIC SCLEROSIS CLASSIFICATION CRITERIA IN THE RESCLE COHORT. Ann Rheum Dis. 2014; 73(2): 709-709. DOI:10.1136/annrheumdis-2014-eular.3769.

Rubio Rivas M, Fonollosa Pla V, Corbella Viros X, Tolosa Vilella C, Colunga Argueelles D, Egurbide Arberas MV, et al. CHANGES IN THE PATTERN OF DEATH IN SYSTEMIC SCLEROSIS. Ann Rheum Dis. 2014; 73(2): 710-710. DOI:10.1136/annrheumdis-2014-eular.1762.

Brito Zeron P, Caminal Montero L, Chamorro A, de la Hera Fernandez J, Gato A, Marin Ballve A, et al. BLOCKING THE HUMAN B LYMPHOCYTE STIMULATOR MOLECULE (BLYS) USING A MONOCLONAL ANTIBODY (BELIMUMAB) IN SYSTEMIC LUPUS ERYTHEMATOSUS: FIRST RESULTS IN REAL-LIFE SPANISH PATIENTS WITH REFRACTORY DISEASE (BIOGEAS-SEMI REGISTRY). Ann Rheum Dis. 2014; 73(2): 985-985. DOI:10.1136/annrheumdis-2014-eular.5447.

Iniesta N, Espinosa G, Fonollosa V, Tolosa C, Egurbide MV, Saez Comet L, et al. ANTI-RNA POLYMERASE III AND ANTI PM/SCL ANTIBODIES: PREVALENCE AND CLINICAL ASSOCIATIONS IN A LARGE COHORT OF SPANISH PATIENTS WITH SYSTEMIC SCLEROSIS. Ann Rheum Dis. 2014; 73(2): 1014-1014. DOI:10.1136/annrheumdis-2014-eular.4098.

Mayes MD, Bossini Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, et al. Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. Am J Hum Genet. 2014; 94(1): 47-61. DOI:10.1016/j.ajhg.2013.12.002.

Gutierrez Fernandez A, Palomino A, Matute C, Gonzalez Pinto A, Ugarte A, Hernanz M, et al. Novel association of Neuregulin 1 gene with bipolar disorder but not with schizophrenia. Schizophr Res. 2014; 159(2-3): 552-553. DOI:10.1016/j.schres.2014.09.001.

Lahera G, Bayon C, Fe Bravo Ortiz M, Rodriguez Vega B, Barbeito S, Saenz M, et al. Mindfulness-based cognitive therapy versus psychoeducational intervention in bipolar outpatients with sub-threshold depressive symptoms: a randomized controlled trial. BMC Psychiatry. 2014; 14(1): 215-215. DOI:10.1186/s12888-014-0215-x.

Ruiz-Irastorza G, Danza A, Khamashta M. Treatment of systemic lupus erythematosus: Myths, certainties and doubts. Med Clin. 2013;141:533-42. FI: 1,399(Q2)

Carmen Cenit M, Marquez A, Cordero-Coma M, Gorrono-Echebarria M, Fonollose A, Adan A, et al. No Evidence of Association between Common Autoimmunity STAT4 and IL23R Risk Polymorphisms and Non-Anterior Uveitis. PLoS One 2013;8:e72892. FI: 3,730(Q1)

Hanly JG, Urowitz MB, O'Keeffe AG, Gordon C, Bae SC, Sanchez-Guerrero J, et al. Headache in Systemic Lupus Erythematosus Results From a Prospective, International Inception Cohort Study. Arthritis Rheum. 2013;65:2887-97. FI: 7,477(Q1)

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Peschken C, et al: SLICC. Breast Cancer In Systemic Lupus (SLE): Do Demographic and Clinical Factors, Including DNA serology, Influence Risk?. Arthritis Rheum. 2013;65:252. FI: 7,477(Q1). ( Meeting Abstract)

Hanly JG, Urowitz MB, o'Keeffe A, Gordon C, Bae SC, Sanchez-Guerrero J, et al.``Lupus Headache'': Results From a Prospective, International, Inception Cohort Study. Arthritis Rheum. 2013;65:675-6. FI: 7,477(Q1). ( Meeting Abstract)

van Vollenhoven RF, Mild M, Doria A, Doerner T, Ferraccioli G, Houssiau F, et al;  IRBIS-EMA Grp. Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients. Arthritis Rheum. 2013;65:684. FI: 7,477(Q1). ( Meeting Abstract)

Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22:1286-94. FI: 2,783(Q2)

Martin JE, Assassi S, Diaz-Gallo LM, Broen JC, Simeon CP, Castellvi I, et al. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol Genet. 2013;22:4021-9. FI: 7,692(Q1)

Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013;72:1308-14. FI: 9,111(Q1)

Ruiz-Irastorza G, Petri M, Gordon C, Khamashta M. Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al. Arthritis Care Res. 2013;65:1391-2. FI: 3,731(Q2)

Ochoa E, Iriondo M, Bielsa A, Ruiz-Irastorza G, Estonba A,  Zubiaga AM. Thrombotic Antiphospholipid Syndrome Shows Strong Haplotypic Association with SH2B3-ATXN2 Locus. PLoS One. 2013;8:e67897. FI: 3,730(Q1)

Cénit MC, Márquez A, Cordero-Coma M, Fonollosa A, Adán A, Martínez-Berriotxoa A, et al. Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition. BMC Med Genet. 2013;14:52. FI: 2,536(Q3)

Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: An updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. FI: 8,145(Q1)

Gladman DD,  Ibanez D, Ruiz I, Urowitz MB. Recommendations for Frequency of Visits to Monitor Systemic Lupus Erythematosus in Asymptomatic Patients: Data from an Observational Cohort Study. J Rheumatol. 2013;40:630-3. FI: 3,258(Q2)

Arana B, Fonollosa A, Artaraz J, Martinez-Berriotxoa A, Martinez-Alday N. Macular hole secondary to toxoplasmic retinochoroiditis. Int Ophthalmol. 2013 : -0. FI: 0,000(Q0)

Carmona DF, Martin JE, Lorenzo B, Simeon CP, Carreira PE, Callejas JL,  et al; Spanish Scleroderma Grp. The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. PLoS One. 2013;8:e54419. FI: 3,730(Q1)

Ramos-Casals M, Ruiz-Irastorza G, Jimenez-Alonso J, Khamashta MA. SEMI. Recommendations on the use of belimumab in systemic lupus erythematosus. GEAS-SEMI. Clinical Practice Guide. Rev Clin Esp. 2013;213:42-58. FI: 2,008(Q2)

Ramos-Casals M, Ruiz-Irastorz G, Jimenez-Alonso J, Khamashta MA, SEMI. Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice. Rev Clin Esp. 2013;213:66-7. FI: 2,008(Q2)

Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, et al. Breast Cancer in Systemic Lupus Erythematosus. Oncology. 2013;85:117-21. FI: 2,165(Q3)

Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide MV, Aguirre C. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev. 2013;12:410-5. FI: 7,975(Q1)

Guillevin L, Hunsche E, Denton CP, Krieg T, Schwierin B, Rosenberg D, et al; DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the duo registry. Clin Exp Rheumatol. 2013;31(suppl 2):71-80.

Diaz-Gallo LM, Simeon CP, Broen JC, Ortego-Centeno N, Beretta L, Vonk MC, et al; Spanish Scleroderma Group. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis. 2013;72:1233-8.

Teruel M, Simeon CP, Broen J, Carreira P, García de la Peña P, Aguirre MÁ, et al; Spanish Scleroderma Group. The role of the NLRP1 gene in systemic sclerosis: a replication study. Clin Exp Rheumatol. 2013;2(Suppl 76):187-8.

Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56-64.

Tesis del grupo

Autor/a: Guillermo Barreiro. Título: "Quantitative analyses in basic, translational and clinical biomedical research: metabolism, vaccine design and preterm delivery prediction". Director/a: Dr. Guillermo Ruiz Irastorza.

© 2022 IIS Biocruces Bizkaia